MENU

 
 

 

OUR SCIENCE

EMD Serono is a science-led organization of curious minds dedicated to delivering transformative medicines that can make a difference in the lives of people affected by cancer

OUR DEVELOPMENT PRIORITIES

EMD Serono leverages our synergistic portfolio in three key areas:

01

Antibody-Drug Conjugates

LEARN MORE

02

DNA Damage Response

LEARN MORE

03

Apoptosis Enhancers

LEARN MORE

Explore our pipeline to see our curiosity in action.

DOWNLOAD PDF

OUR LEGACY AREAS

04

Immuno-oncology

LEARN MORE

05

Oncogenic Signaling

LEARN MORE

OUR SPOTLIGHT

Our curiosity drives us to transform the standard of care for challenging cancers.

Look at MET

How do MET alterations drive oncogenesis in non-small cell lung cancer (NSCLC)? How do these alterations arise, and how do they impact patient prognosis? If you have patients with MET alterations, visit our website to learn more about testing options and additional information that can help inform treatment decisions for your patients with NSCLC.

VISIT WEBSITE
DNA-damage-response

DNA Damage Response

Is the DNA damage response pathway a viable target for cancer therapy? This video discusses the key protein kinases implicated in DDR pathways and the potential implications of inhibition of these pathways in cancer.

WATCH VIDEO

Abbreviations:
DDR, DNA damage response; MET, mesenchymal epithelial transition factor.

© 2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. EMD Serono, Inc. is the healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada.

US-MULO-00051
Last updated 07/2023

Are You a Healthcare Professional?

Yes
No